E Simon1, M Schwarz, U Wendel. 1. Department of General Pediatrics, Heinrich Heine University, Düsseldorf, Germany. simon@med.uni-duesseldorf.de
Abstract
BACKGROUND: In MSUD, dietary treatment aims at the protection of the brain from functional disturbances and structural damage by keeping the branched-chain amino acids in plasma permanently in the near-normal range. Unfortunately, delay in effective treatment of the neonatal manifestation and poor long-term metabolic control are common in MSUD patients, leading to impaired cognitive outcome. Some studies have analysed cognitive capacity but only few data are available on social status (educational qualification, interpersonal relationships, lifestyle) in adult patients, which is one measure for the success of treatment. AIM: In this study we analysed sociodemographic data of 22 adult patients suffering from classic or very severe variant MSUD in comparison with data on an age-matched control collective of the population of Germany. RESULTS: The analysis revealed low educational and professional levels with a low rate of participation in the labour force by adult MSUD patients. The educational level in patients of migrant origin was lower than the educational qualifications in the native patient group. A large number of patients did not live a normal adult life. Patients could not live autonomously, did not have a steady partnership and had no children. CONCLUSION: Despite substantial improvement in the treatment of MSUD in recent years, unimpaired outcome of patients with classic or very severe variant MSUD remains a rare finding. Care must be further optimized in order to improve intellectual and, thereby, social outcome. Particular care must be exercised in the treatment of migrant patients who offer special problems due to cultural peculiarities and language difficulties.
BACKGROUND: In MSUD, dietary treatment aims at the protection of the brain from functional disturbances and structural damage by keeping the branched-chain amino acids in plasma permanently in the near-normal range. Unfortunately, delay in effective treatment of the neonatal manifestation and poor long-term metabolic control are common in MSUDpatients, leading to impaired cognitive outcome. Some studies have analysed cognitive capacity but only few data are available on social status (educational qualification, interpersonal relationships, lifestyle) in adult patients, which is one measure for the success of treatment. AIM: In this study we analysed sociodemographic data of 22 adult patients suffering from classic or very severe variant MSUD in comparison with data on an age-matched control collective of the population of Germany. RESULTS: The analysis revealed low educational and professional levels with a low rate of participation in the labour force by adult MSUDpatients. The educational level in patients of migrant origin was lower than the educational qualifications in the native patient group. A large number of patients did not live a normal adult life. Patients could not live autonomously, did not have a steady partnership and had no children. CONCLUSION: Despite substantial improvement in the treatment of MSUD in recent years, unimpaired outcome of patients with classic or very severe variant MSUD remains a rare finding. Care must be further optimized in order to improve intellectual and, thereby, social outcome. Particular care must be exercised in the treatment of migrant patients who offer special problems due to cultural peculiarities and language difficulties.
Authors: George V Mazariegos; D Holmes Morton; Rakesh Sindhi; Kyle Soltys; Navdeep Nayyar; Geoffrey Bond; Diana Shellmer; Benjamin Shneider; Jerry Vockley; Kevin A Strauss Journal: J Pediatr Date: 2011-08-11 Impact factor: 4.406
Authors: Nicola Brunetti-Pierri; Brendan Lanpher; Ayelet Erez; Elitsa A Ananieva; Mohammad Islam; Juan C Marini; Qin Sun; Chunli Yu; Madhuri Hegde; Jun Li; R Max Wynn; David T Chuang; Susan Hutson; Brendan Lee Journal: Hum Mol Genet Date: 2010-11-23 Impact factor: 6.150
Authors: Giselli Scaini; Tássia Tonon; Carolina F Moura de Souza; Patricia F Schuk; Gustavo C Ferreira; Joao Seda Neto; Tatiana Amorin; Ida Vanessa D Schwartz; Emilio L Streck Journal: Mol Neurobiol Date: 2016-09-22 Impact factor: 5.590
Authors: D Klee; E Thimm; H J Wittsack; D Schubert; R Primke; G Pentang; J Schaper; U Mödder; A Antoch; U Wendel; M Cohnen Journal: J Inherit Metab Dis Date: 2013-01-25 Impact factor: 4.982
Authors: Kevin A Strauss; Bridget Wardley; Donna Robinson; Christine Hendrickson; Nicholas L Rider; Erik G Puffenberger; Diana Shellmer; Diana Shelmer; Ann B Moser; D Holmes Morton Journal: Mol Genet Metab Date: 2010-01-12 Impact factor: 4.797
Authors: William J Zinnanti; Jelena Lazovic; Kathleen Griffin; Kristen J Skvorak; Harbhajan S Paul; Gregg E Homanics; Maria C Bewley; Keith C Cheng; Kathryn F Lanoue; John M Flanagan Journal: Brain Date: 2009-03-17 Impact factor: 13.501